India biopharma revenues rise to $2.5 bn

Moreover, the vaccines sector in India, which is a major supplier of vaccines to UNICEF, within the biopharma space witnessed a continued growth in 2011-12, with companies like Haffkine Biopharmaceutical and Serum Institute recording high growth of 100 percent and 60 percent respectively. Also, the animal vaccine market, which is about $60-to-70 million, registered a 15 percent .

Furthermore, the diagnostics market in India also witnessed 20 percent growth, which is the faster than any country in the world (the growth in the US being only one-to-two). Lets hope that by looking at the scope of growth in the various domains of the biopharma sector, the government takes further steps to provide encouragement to this sector.